10-Q · May 11, 2026
Septerna, Inc. reported a significant increase in revenue in Q1 2026, hitting $26.5 million, a considerable rise from $21 million reported in Q4 2025 and far exceeding the $75 million consensus estimate. The gross…
Earnings analysis · 10-Q
SEPN earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text indicates improving six-month losses and substantial liquidity, with $516.5 million of cash, cash equivalents and marketable securities expected to fund operations at least into 2029. However,…
Read full summary
The supplied 10-Q text indicates improving six-month losses and substantial liquidity, with $516.5 million of cash, cash equivalents and marketable securities expected to fund operations at least into 2029. However, Septerna remains a clinical-stage biotechnology company with no product-sales revenue, an accumulated deficit of $188.9 million and significant ongoing development risk. The key incremental risks are potential restrictions involving WuXi AppTec under the BIOSECURE Act, rising regulatory and cybersecurity compliance requirements, and the expected loss of smaller-reporting-company status after fiscal 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Six-Month Loss Narrowed
Six-month net loss improved to $21.7 million from $46.3 million in the comparable 2025 period, a $24.6 million reduction in losses.
-
Strong Liquidity Runway
Cash, cash equivalents and marketable securities totaled $516.5 million as of June 30, 2026, which management expects to fund operations and capital expenditures at least into 2029.
-
Pipeline Capital Reprioritized
Management is reallocating IPO proceeds following discontinuation of SEP-786 to advance SEP-479 and SEP-631 in clinical development and continue other pipeline programs.
-
Clinical Pipeline Advancing
SEP-479 entered a Phase 1 trial in Australia in April 2026, while SEP-631 had Phase 1 data presented on March 1, 2026.
-
Organization Expanded
The company had 123 full-time employees as of June 30, 2026, supporting expansion of clinical development, regulatory and operational capabilities.
-
Controls Remained Effective
Disclosure controls and procedures were concluded effective at a reasonable-assurance level as of June 30, 2026, with no material changes to internal control over financial reporting during the quarter.
What to watch
-
Persistent Losses and No Product Revenue
The company had an accumulated deficit of $188.9 million as of June 30, 2026 and expects significant losses for the foreseeable future. It has no approved products and has generated $0 of product-sales revenue to date.
-
Future Financing Remains a Risk
Although management expects $516.5 million of liquidity to fund operations at least into 2029, the estimate depends on assumptions that may prove incorrect, and the company has no committed sources of additional capital.
-
WuXi AppTec Supply-Chain Exposure
WuXi AppTec was added to the Department of Defense Section 1260H list on June 6, 2026. The filing states that formal designation as a Biotechnology Company of Concern is expected after publication of the final list no later than December 18, 2026, potentially restricting future U.S. government contracts, grants or loans.
-
Prior Lead Program Discontinued
The company discontinued SEP-786 after observing two unanticipated severe Grade 3 events of elevated unconjugated bilirubin in the Phase 1 trial, underscoring clinical safety and program discontinuation risk.
-
Upcoming Reporting Cost Increase
The company expects to lose smaller-reporting-company status after fiscal 2026 and anticipates that its March 31, 2027 Form 10-Q will no longer qualify for those scaled disclosure accommodations, increasing compliance costs.
-
Expanding AI and Cyber Compliance
The company is exposed to evolving data and AI regulation: the EU AI Act’s remaining provisions generally became applicable August 2, 2026, while NIS 2 may impose fines of up to the higher of €10 million or 2% of worldwide turnover.
Management's outlook
No explicit numeric revenue or EPS guidance was identified in the supplied 10-Q text. Management states that $516.5 million of cash, cash equivalents and marketable securities is expected to fund operating expenses and capital expenditure requirements at least into 2029.
Earlier filings 4
10-K · March 9, 2026
Septerna positions itself as a clinical-stage GPCR drug-discovery company built around its proprietary Native Complex Platform® and is advancing a diversified oral small-molecule pipeline across endocrinology,…
10-Q · August 11, 2025
Septerna reported Q2 revenue of $119,000 and GAAP net loss of $24.8 million (EPS $(0.56)), with revenue down materially versus both the prior quarter ($219,000 in Q1 2025) and the year-ago quarter ($370,000 in Q2 2024).…
10-Q · May 15, 2025
Septerna reported revenue of $219,000 and a GAAP net loss of $21.5 million (net loss per share $0.49) for the quarter ended March 31, 2025. R&D and G&A spending rose materially year-over-year, driving operating loss of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.